From a technical point of view, ICL intraocular lens implantation is to implant an intraocular lens in the patient's phakic eye to maintain the natural accommodation function of the lens and adjust the refraction at the same time. Its advantages are high safety and predictability, and reversible operation. The surgical procedure is to implant an intraocular lens from a small incision to correct vision.

From the international and domestic authoritative certification, ICL surgery is another innovative scientific and technological achievement in the field of modern ophthalmic refractive correction. It has been certified by FDA of the United States and CE of Europe, approved by People's Republic of China (PRC) and FDA of the United States, and allowed to enter the medical device market in China [registration number: State FDA (J) No.3221129]. The raw material of ICL is collagen polymer [Collamer] exclusively produced by STAAR Company in the United States. It is polymerized from a small amount of purified collagen, which has good biocompatibility and no adverse reactions in the eyes.

Judging from the surgical cases, there are nearly 300,000 ICL implanted contact lenses in the world. ICL surgery has an incomparable superior effect in correcting ultra-high myopia compared with traditional excimer laser surgery. Its high efficiency and safety have been practiced in many clinical practices at home and abroad, opening up a new field of refractive surgery.